PDL BioPharma Inc. (Public, NASDAQ:PDLI) - PDL BioPharma Announces November 2 Webcast of Third Quarter 2006 Financial Results Conference Call
PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI - News) today announced that it will release its financial results for the third quarter 2006 following the close of the U.S. financial markets on Thursday, November 2, 2006. PDL will hold a conference call to discuss these financial results, its commercial and clinical activities and its forward-looking information and guidance at 4:30 p.m. Eastern time on November 2, 2006. A live webcast of the conference call will be available through the PDL website: www.pdl.com . Please connect to this website at least 15 minutes prior to the live webcast to allow time for any software download that may be needed to hear the webcast. Financial and statistical information to be discussed in the call will be available on the PDL website immediately prior to the commencement of the call. A replay will be available at www.pdl.com starting approximately one hour after completion of the webcast. An audio replay will also be available by telephone from approximately 6:30 p.m. Eastern time on November 2, 2006 through 6:30 p.m. Eastern time on December 3, 2006. To access the replay, dial 888-203-1112 from inside the U.S. and 719-457-0820 from outside the U.S.; enter conference ID number 2444267. About PDL BioPharma PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses. The company currently markets and sells a portfolio of leading products in the acute-care hospital setting in the United States and Canada and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies based on its pioneering antibody humanization technology. Currently, PDL's diverse product pipeline includes investigational compounds in Phase 2 or Phase 3 clinical development for inflammation and autoimmune diseases, cardiovascular disorders and cancer. The company's research platform is focused on the discovery and development of antibodies for the treatment of cancer and autoimmune diseases. For more information, please see PDL's website at www.pdl.com . NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc. --------------------------------------------------------------------- ----------- Source: PDL BioPharma, Inc. http://tech.groups.yahoo.com/group/biotech-news/ http://www.arizonabiotech.com/ http://www.azhttp.com/ http://www.arizonabiotech.com/ http://groups.yahoo.com/group/biotech-news/ http://www.arizonaentrepreneurs.com/ http://www.azhttp.com/ Yahoo! Groups Links <*> To visit your group on the web, go to: http://groups.yahoo.com/group/biotech-news/ <*> Your email settings: Individual Email | Traditional <*> To change settings online go to: http://groups.yahoo.com/group/biotech-news/join (Yahoo! ID required) <*> To change settings via email: mailto:[EMAIL PROTECTED] mailto:[EMAIL PROTECTED] <*> To unsubscribe from this group, send an email to: [EMAIL PROTECTED] <*> Your use of Yahoo! Groups is subject to: http://docs.yahoo.com/info/terms/
